Manage Your Liver
Q:

Hep C News: Only heading in a new direction of treatment will help prevent deaths

Hep C News: Only heading in a new direction of treatment will help prevent deaths
A:

Recent data released by the Centre for Disease Control and Prevention (CDC) showed that the deaths associated with hepatitis C reached an all-time high of 19,659 in 2014. Since 2013, the annual hepatitis C-related mortality surpassed the total combined number of deaths from 60 other infectious diseases. [1]

 

Although the effectiveness of  the recently introduced hepatitis C antiviral treatment (DAA) is higher than previous drugs, this new treatment does not directly reduce liver damage nor improve liver health. [2] Together with the data released by CDC, it is suggested that the DAA treatments are not able to lower the number of deaths related to hepatitis C.

 

The only function of antiviral drugs is to eliminate the hepatitis virus in the human body, thus, to regain liver health, the liver must recover itself using its unique self-repairing ability. However using drugs actually causes further damage to the liver as the drug itself contains toxicity. A recent published paper has found that using DAA treatment might have an impact on the immune system as there is a sudden change of viral count, thus dramatically increasing the risk of liver cancer. [3] The number of related deaths caused by hepatitis C is continuously increasing; this is a clear indication that it is time to reconsider current treatment direction.

 

From the patients’ point of view, the primary objective of treatment should be to ensure normal liver function (ALT level), to reduce and prevent liver fibrosis, and to improve the quality of daily life. Only by successfully carrying out these objectives can one ensure long term liver health protection, reduce the likelihood of severe liver diseases and lower the risk of deaths caused by liver inflammation related diseases.

 

Disclaimer:
  • * All research and clinical data should be used as reference purposes only, results may vary.
Related Questions
A:
About 2.7 million persons in the United States are infected with hepatitis C virus in their blood. The majority of these individuals remain asymptomatic for many years following the initial infection, and many people can even live their whole life with hepatitis C virus in their body without knowing they are infected. On the other hand, some carriers will develop chronic hepatitis C, meaning that the virus in their body attacks the liver, causing liver damage with elevated alan
A:
Since the introduction of direct-acting antiviral (DAA) therapy, treatment for hepatitis C (HCV) was revolutionized, as patient outcomes are improved with fewer side effects and high cure rate. However, there is significant debate in the society based on studies that suggest HCV cure does not eliminate risk for hepatocellular carcinoma (HCC) or liver cancer. Other research suggests the possibility of increased risk of developing liver cancer during and after DAA treatment in patients with hep
Hit Questions
A:
Hepatitis C is a wide spread and deadly disease affecting an estimated of 3.5 million Americans.   Treatment for hepatitis C has evolved over the years, going from highly toxic drugs involving injections with horrible side effects, to medications with minimal side effects. Success rate of treatment options has also improved greatly Although the high price tag of the new DAA treatment is controversial, it has undoubtedly helped to cure many hepatitis C patients.
A:
Fibrosis is scarring of the liver that results from chronic inflammation. It is a process where the damaged, dying liver cells are replaced by fibrous scar tissue, causing the liver to become hard. The extent of liver fibrosis can vary, and it is often classified in several stages. The most common classification is a scale from F0 to F4. F0 indicates no fibrosis. A normal liver is at a stage between F0 and F1. F2 denotes light fibrosis, and F3 indicates severe fibrosis. When scar tissue build
A:
You probably have already heard about the new antiviral hep C drug, which is effective but insanely expensive. It claims to have around 90% success rate, that’s why so many hepatitis C patients are dying for it even though it’s extremely costly. But apart from its expensive price tag, there is a bigger issue behind this new drug that not many people know about. Scientists and researchers have found an increased risk of extreme liver cancer related to this new drug after successful
A:
Hepatitis C viruses share a common characteristic to other chronic liver diseases; it could damage the patients’ liver cells. Hepatitis C patients should focus on stopping or reducing the damage in the liver, and this focus should be the same for other chronic liver diseases e.g. hepatitis B, fatty liver disease, NASH etc. And this is exactly what YHK can do.   YHK can stop liver cells damage caused by hepatitis viruses, and can repair damaged liver cells, to he
YHK Liver Therapy
Your Liver
Protection

starts here.
Buy YHK
Have Questions?
Sumbit your question to us for profeessional answers!
Looking for help? Ask our customer support team!
Contact Us